Physician profile
Allan Drexl
NPI 1558346692
$1,406.71
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $213 · 2021: $208 · 2022: $437 · 2023: $370 · 2024: $50.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $428.42 | 2020-2024 | Cequa |
| Bausch & Lomb Americas INC. | $294.48 | 2022-2024 | Prolensa, Miebo, Vyzulta |
| Aerie Pharmaceuticals, INC. | $86.43 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $83.51 | 2020-2021 | |
| Glaukos Corporation | $77.14 | 2020 | |
| Eyevance Pharmaceuticals LLC | $70.52 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $59.50 | 2023 | Acthar |
| Alimera Sciences, INC. | $42.96 | 2019 | |
| Dompe US, INC. | $29.13 | 2023 | Oxervate |
| Katena Products, INC. (Dba Corza Medical) | $28.54 | 2019 | |
| Oyster Point Pharma, INC. | $23.45 | 2022 | |
| Kala Pharmaceuticals, INC. | $23.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.52 | 2022 | |
| Shire North American Group INC | $20.75 | 2019 | |
| Rxsight INC | $19.47 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $19.43 | 2023 | |
| Allergan, INC. | $17.69 | 2020 | |
| Biotissue Holdings INC. | $16.39 | 2022 | |
| Omeros Corporation | $15.83 | 2021 | |
| Alcon Vision LLC | $15.28 | 2022 | |
| Eyepoint US, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Drexl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.